RFCA
ALXN

R&F Capital Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

R&F Capital Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		$710K Buy
5,857
+3,061
+109% +$395K 0.18% 163
2016
Q4 		$342K Buy
+2,796
New +$342K 0.12% 272

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

R&F Capital Advisors's ALXN Position: Q1 2017 in Review

R&F Capital Advisors increased its Alexion Pharmaceuticals (ALXN) stake by 109% in Q1 2017, buying an estimated $395K and bringing the position to 5,857 shares worth $710K. The position accounts for 0.18% of the portfolio, ranked #163.

R&F Capital Advisors first reported a position in ALXN in Q4 2016 and has held it in 2 quarters since. 561 funds tracked by Wall St. Rank hold ALXN as of Q1 2017.

  • R&F Capital Advisors held 5,857 shares of Alexion Pharmaceuticals worth $710K as of Q1 2017.
  • R&F Capital Advisors bought 3,061 Alexion Pharmaceuticals shares in Q1 2017, an estimated $395K.
  • Alexion Pharmaceuticals made up 0.18% of R&F Capital Advisors's portfolio in Q1 2017, its #163 holding.
  • R&F Capital Advisors first reported a position in Alexion Pharmaceuticals in Q4 2016 and has held it in 2 quarters since.
  • 561 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2017.

Based on R&F Capital Advisors's 13F filing for Q1 2017, filed 15 May 2017.